This study is a first to demonstrate that inhibition of Kpnβ1 is an effective way to enhance the anti-cancer effects of cisplatin, and that both cisplatin sensitive, HeLa, and the more resistant, SiHa cervical cancer cells were responsive to this treatment. The gene discussed is KPNB1; the disease is cervical cancer.